Explore EVY
Experience the future of cognitive care with EVY — the most comprehensive 40Hz multi-sensory platform of light, sound and tech designed to support those living with Alzheimer’s or dementia as part of a healthy lifestyle.
Meet Dr. Jeffrey L. Cummings
Prof., MD, ScD, Neurology, Cleveland Clinic Lou Ruvo Center for Brain Health, Chair of the ACTC Neuropsychiatric Symptoms Committee, Endowed Professor and “Rock Star of Science”
Dr. Jeffrey L. Cummings
Prof., MD, ScD, Neurology
Dr. Cumming is Vice Chair of Research, UNLV Department of Brain Health. He is the founding director of the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, Nevada, and Professor of Medicine (Neurology), Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.
Dr. Cummings is Principal Investigator & Director of the NIH/NIGMS-funded Center for Neurodegeneration and Translational Neuroscience. Dr. Cummings is also the Joy Chambers-Grundy Professor of Brain Science, an endowed professorship. He is the director of the chambers-Grundy center for transformative neuroscience, a center devoted to using the tools of neuroscience and neurologic drug development to transform people’s lives.
Dr. Cummings is a world-renowned Alzheimer’s researcher and leader of clinical trials. He has been recognized for his research and leadership contributions in the field of Alzheimer’s disease through the Henderson Award of the American Geriatrics Society (2006), the Ronald and Nancy Reagan Research Award of the national Alzheimer’s Association (2008), and the Lifetime Achievement Award of the Society for Behavioral and Cognitive Neurology (2017).
In 2010, he was honored by the American Association of Geriatric Psychiatry with their Distinguished Scientist Award. In 2018, he was honored with the Leadership and Achievement Award by the International Society of CNS Drug Development, and he received the Bengt Winblad Lifetime Achievement Award from the National Alzheimer’s Association. In 2019, the International Psychogeriatric Association awarded him with the Distinguished Service Award and he received the Alzheimer’s Drug Discovery Foundation Melvin R. Goodes Prize that honors an innovative researcher who has made a significant and lasting impact in the field. Lastly, he was featured in the Gentleman’s Quarterly (June 2009) as a “Rock Star of Science™.”
How Jeffrey Supports Optoceutics
Dr. Jeffrey Cummings’ contributions to Optoceutics through his extensive background in Alzheimer’s disease research and clinical trial leadership empower the company with strategic insights that enhance trial design and execution.
Current or Past Scientific Advisory Boards:
Acadia, Actinogen, Acumen, AlphaCognition, ALZpath, Aprinoia, AriBio, Artery, Biogen, Biohaven, BioVie, BioXcel, Bristol-Myers Squib, Cassava, Cerecin,Diadem, Eisai, GAP Foundation, GemVax, Janssen, Jocasta, Karuna, Lighthouse, Lilly, Lundbeck, LSP/eqt, Mangrove Therapeutics, Merck, NervGen, New Amsterdam, Novo Nordisk, Oligomerix, ONO, Otsuka, Oxford Brain Diagnostics, Prothena, ReMYND, Roche, Sage Therapeutics, Signant Health, Simcere, sinaptica, Suven, TrueBinding, Vaxxinity, and Wren pharmaceutical, assessment, and investment companies.
New: Independent Memory Care Study
EVY is a general wellness product and is not intended to diagnose, treat, prevent, or cure any disease or medical condition.
